S1102
Clinical – Upper GI
ESTRO 2026
(PFS) was 29.6 months (95% CI 15.1-44.2), with 1- and 2- year PFS rates of 76.3% and 52.5% respectively. Median local PFS was not reached with 1- and 2-year local control rates of 94.0% and 89.7%. Median intrahepatic PFS was 41.3 months (95% CI 21.9 – 60.8) and median extrahepatic PFS was not reached. Conclusion: Liver SBRT achieves excellent and durable local control rates of approximately 90% at 2 years, with predominantly low-grade toxicities, supporting its role as a safe and effective treatment for patients with HCC. The overall survival rates are encouraging for a cohort of patients with multiple medical comorbidities and/or disease refractory to previous liver directed therapies. Keywords: Liver SABR, HCC, Clinical Outcomes Nodal Irradiation in Pancreatic Cancer: A Systematic Review and Meta-Analysis Vannesza Hendricke C. Chua, Carl Jay E. Jainar, Patricia J. Ong, Leona Marie Francesca S. Rebosa, Bryce Matthew L. Tan De Guzman, Ryan Anthony F. Agas Department of Radiation Oncology, Benavides Cancer Institute, Manila, Philippines Purpose/Objective: Treatment volumes for nodal irradiation in locally advanced (unresectable) pancreatic cancer is a topic of debate, with varying opinions on involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI). This study aims to synthesize the current evidence on IFRT and ENI in the context of chemoradiation for locally advanced pancreatic cancer. Material/Methods: The following databases were searched for relevant articles published from January 2000 to November 2025: PubMed, ScienceDirect, EBSCOhost Academic Databases, Scopus, and Cochrane Library. Literature appraisal was done. Data on locoregional failure (LRF), objective tumor response, overall survival (OS), and Digital Poster 3491 toxicity was extracted. Objective tumor response (complete or partial) was assessed via the Response Evaluation Criteria in Solid Tumours, while toxicity was graded using the Common Terminology Criteria for Adverse Events version 3.0. Results: This analysis included 35 studies: 15 IFRT-only, 19 ENI- only, and one comparative retrospective study. This was composed of 19 cohort studies and 16 clinical trials (11 phase II, five phase III). LRF in the IFRT group was 30% (95% CI: 29-31), versus 29% (95% CI: 18-41) for the ENI group. Objective tumor response after IFRT was 31% (95% CI: 21-44), compared to 21% (95% CI:
Digital Poster 3418 Real-World Outcomes of patients with
Hepatocellular Carcinoma (HCC) Treated with Liver Stereotactic Ablative Radiotherapy (SBRT) in West Yorkshire, UK Yan Ling Pang 1 , Louise Murray 1 , Animesh Saha 2 , David Wilson 3 , Suchandana Bhaumik 1 , Rebecca Goody* 1 , Nathalie Casanova* 1 1 Oncology, Leeds Cancer Centre, Leeds, United Kingdom. 2 Oncology, Apollo Multi-speciality Hospital, Kolkata, India. 3 Oncology, South Tees Hospital Foundation, Middlesbrough, United Kingdom Purpose/Objective: Background:Introduced in England in 2016, liver SBRT is an established treatment option for patients with hepatocellular carcinoma (HCC) who are unsuitable for surgery, or as an alternative to ablation or transarterial chemo-embolization (TACE).Objectives:Aretrospective single-centre studywas conducted to evaluate baseline patient characteristics, early treatment-related toxicities, and clinical outcomes among patients with HCCtreated withSBRT. Material/Methods: Patients with HCC treated with SBRT between April 2017-December 2024 were included. Treatment comprised alternate-day 5-fraction VMAT SABR with 4D-cone-beam CT image-guidance. Baseline and follow-up data were extracted from electronic records. Kaplan-Meier analysis was used to evaluate outcomes. Results: In total 129 patients (median age: 74 years, range 30– 93) received SBRT. Child-Pugh status was A5 in 58%, A6 in 40% and ungraded in 2%. Alcohol and metabolic dysfunction-associated steatotic liver disease (MASLD) were the most common aetiologies of underlying cirrhosis. Fifteen lesions demonstrated macrovascular invasion. The majority had good functional status:15% were performance status (PS) 0, 52% PS 1, 29% PS 2, 3% PS1/2, 1% PS 2/3 and 1% unknown.44% had received prior treatment to the target lesion before liver SBRT. Median number of treated HCCs was 1 (range 1–3) and median lesion size was 2.8 cm (0.7–6.0 cm). Five patients did not complete treatment due to factors including poor compliance, treatment-related thrombocytopenia, patient-initiated discontinuation, and one mortality from a non-treatment related condition. Among completers, median prescribed dose was 45 Gy (range 25–50). At 6 weeks, 47% reported toxicities, of which 86% were grade 1, most commonly fatigue and mild transaminitis. One patient was admitted with grade 3 toxicity for pain management. Median overall survival (OS) was 31.4 months (95% CI 21.7 – 41.1) with 1- and 2- year OS rates of 88.4% and 65.9% respectively. Median progression-free survival
Made with FlippingBook - Share PDF online